AIM - AIM ImmunoTech completes dosing in Cohort 3 of early-stage Ampligen trial

AIM ImmunoTech (AIM) has completed dosing of Cohort 3 in a Phase 1 study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.No serious adverse events were reported. This is consistent with results in the first two cohorts of the study and at escalating doses.Subjects in Cohort 1 received 75 ?g of Ampligen, subjects in Cohort 2 received 200 ?g and subjects in Cohort 3 received 500 ?g.The study is already proceeding with Cohort 4, with subjects receiving 1250 ?g.AIM shares up 5% premarket trading at $2.14.Last month, the company completed dosing of Cohort 2 in a Phase 1 study and reported no serious adverse events.

For further details see:

AIM ImmunoTech completes dosing in Cohort 3 of early-stage Ampligen trial